Akebia Therapeutics (AKBA) Research & Development (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Research & Development of $14.8 million for Q1 2026, up 51.8% year-over-year from $9.8 million in Q1 2025, and up 1380.7% quarter-over-quarter from $1.0 million in Q4 2025.
Akebia Therapeutics (AKBA) Research & Development (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Research & Development for 14 consecutive years, with $14.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 51.8% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $41.8 million (up 10.86% YoY), while the FY2025 annual figure was $62.4 million, up 65.62% from the prior year.
- Research & Development advanced to $14.8 million in Q1 2026 per AKBA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Research & Development topped out at $43.8 million in Q1 2022 and bottomed at $1.0 million in Q4 2025.
- Historically, Research & Development has averaged $16.6 million across 5 years, with a median of $13.3 million in 2023.
- On a YoY basis, Research & Development climbed as much as 76.08% in 2025 and fell as far as 91.52% in 2025.
- Akebia Therapeutics' Research & Development stood at $32.1 million in 2022, then slumped by 69.27% to $9.9 million in 2023, then gained by 19.47% to $11.8 million in 2024, then slumped by 91.52% to $1.0 million in 2025, then jumped by 1380.7% to $14.8 million in 2026.
- Business Quant data shows AKBA's Research & Development at $14.8 million in Q1 2026, $1.0 million in Q4 2025, and $14.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 14.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.06 Mn |
| Mar 31, 2026 | 14.81 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 14.94 Mn |
| Jun 30, 2025 | 11.01 Mn |
| Mar 31, 2025 | 9.75 Mn |
| Dec 31, 2024 | 11.79 Mn |
| Sep 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 7.65 Mn |
| Mar 31, 2024 | 9.73 Mn |
| Dec 31, 2023 | 9.87 Mn |
| Sep 30, 2023 | 13.33 Mn |
| Jun 30, 2023 | 20.20 Mn |
| Mar 31, 2023 | 19.69 Mn |
| Dec 31, 2022 | 32.10 Mn |
| Sep 30, 2022 | 28.03 Mn |
| Jun 30, 2022 | 26.03 Mn |
| Mar 31, 2022 | 43.83 Mn |
| Dec 31, 2021 | 29.56 Mn |
| Sep 30, 2021 | 40.47 Mn |